**6. Conclusion**

*De novo* drug development is being time consuming, costly and risk-prone venture 'drug repurposing' has drawn attention of all pharma companies and R and D sectors which offers faster and cheaper ways for bringing new drugs into the market especially for targeting ODs. Based upon the benefits provided by drug repurposing, the development of more sophisticated and systematic approach is required to find more drug candidates that can be fitted into the picture of promising targets for repurposing.

**75**

**Author details**

, Ashish Jain†

Research (PGIMER), Chandigarh, India

† All authors have equal contribution.

provided the original work is properly cited.

, Dhruv Mahendru†

\*Address all correspondence to: drbikashus@yahoo.com

Department of Pharmacology, Postgraduate Institute of Medical Education and

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

, Ajay Prakash and Bikash Medhi\*

Neha Dhir†

*Drug Repurposing and Orphan Disease Therapeutics DOI: http://dx.doi.org/10.5772/intechopen.91941*
